The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Novartis has formed its third partnership with a China-based drugmaker since the start of 2025, signing a potentially $900 million deal with Boomray Therapeutics centered around a radiopharmaceutical for cancer.

    Updated 9 hours ago
  • Female doctor talking with a diverse team of medical professionals during a meeting around a conference table in a hospital
    Image attribution tooltip
    Goodboy Picture Company via Getty Images
    Image attribution tooltip
    Sponsored by Lucid Group

    Are healthcare systems really ready for GLP-1s?

    New GLP-1 therapy indications mean new challenges for pharma companies, from care to consumer trust.

  • A picture of tablets and injectable medicines for obesity.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares surge on updated obesity drug data

    Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

  • A micrograph of a mast cell or mastocyte, with smooth muscle fibers stained in blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Celldex sinks as safety concerns cloud immune drug results

    Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

  • A headshot of Kabir Nath, CEO of Compass Pathways.
    Image attribution tooltip
    Permission granted by Compass Pathways
    Image attribution tooltip
    Q&A // Brain drug revival

    How J&J paved the way for Compass’ coming psychedelic drug launch

    In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’

    Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Iambic Therapeutics, a Nvidia-backed AI drug discovery specialist, is one of three biotechs that have publicly revealed IPO plans since last Friday.

    Updated Sept. 22, 2026
  • A close-up of a person's brown eye.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beacon eye gene therapy hits mark in late-stage study

    Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo talks up drug launches in effort to win back investors

    At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: GSK’s China deals, the $300M IPO club and selling the news

    The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Xenon shares fall following depression trial pause

    The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

    Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Electra amasses $350M in biotech’s latest big IPO

    Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lisata deal propels Marea’s drug pipeline to Wall Street

    Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    North Immunology joins biotech reverse merger boom with Aethlon deal

    Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Roche, Dualitas team up to find bispecific drugs for immune diseases

    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to pay $125M for blood-brain barrier crossing platform

    Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

  • A low-angle, full shot of the Nasdaq MarketSite building in Times Square under a bright, overcast sky, featuring a large, curved blue digital billboard. The billboard displays a welcome message reading "Nasdaq Welcomes Faeth Therapeutics, June 23, 2026," alongside the Faeth logo and "FTH Nasdaq Listed."
    Image attribution tooltip
    Permission granted by Faeth Therapeutics
    Image attribution tooltip
    Deep Dive

    A booming business on Wall Street would love more biotechs to quietly die

    Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.

  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo partners with Orbis, deepening investment in oral peptide drugs

    The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

  • An illustration of a cancerous tumor inside the lungs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

    The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    FDA launches pilot program to speed up early US drug research

    First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing. 

    FDA
  • OpenAI ChatGPT and Anthropic Claude application icons shown on screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

    The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Sling banks $123M for an experimental thyroid eye disease pill

    A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Skyhawk racks up more support for Huntington’s drug

    The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA clears first generic radioligand drug; Sionna turns to layoffs

    A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.